Even orphan drugs for rare diseases have been commercialized for individualized pharmacological approaches, such as Fenfluramine and Cannabidiol for Dravet syndrome and Lennox–Gastaut syndrome, or ganaxolone for CDKL5-mediated epilepsies [16,17,18]. Here, CDKL5 is linked to epilepsy.